Apraclonidine and pilocarpine have been shown to be effective in reducing the incidence of intraocular pressure (IOP) spikes following argon laser trabeculoplasty. An additional reduction in the incidence of acute pressure rise might theoretically be expected by combining these two effective agents. In a prospective randomised study we compared the ability of apraclonidine and pilocarpine alone and in combination to prevent post laser pressure spikes. Patients receiving regular pilocarpine to either eye were excluded. Seventy five eyes received either apraclonidine (26 eyes), pilocarpine (23 eyes), or both drugs (26 eyes). Apraclonidine 1% was instifflled 1 hour before and immediately after, and pilocarpine 4% immediately after trabeculoplasty. IOP was measured before and at 1, 2, and 3 hours following trabeculoplasty. In only two (8%) -eyes receiving combined treatment was a pressure rise observed. This frequency was significantly lower than that seen in eyes treated with apraclonidine alone (38%), or pilocarpine alone (39%). The mean fall in IOP at 1, 2, and 3 hours was significantly greater in those eyes receiving combined treatment than in the other two groups. (BrJ Ophthalmol 1994; 78: 30-32) 
Argon laser trabeculoplasty (ALT) now has an established place in the treatment of raised intraocular pressure (IOP). However, over the past 10 
Influence ofapraclonidine andpilocarpine alone and in combination on post laser trabeculoplasty pressure rise In this study, we have shown that apraclonidine and pilocarpine in combination appear to provide significantly better protection against pressure spikes than either alone. A small rise in IOP (less than 1 mm Hg) was seen in two eyes (8%) in group C compared with 10 eyes (38%) in group A and nine eyes (39%) in group B (median 5 5 mm Hg and 2 7 mm Hg) respectively. The rise seen in the two eyes in group C is less than 1 mm Hg which is probably not clinically significant.
In our study, no eyes had a pressure rise of more than 10 mm Hg. We postulate two reasons why this might be so. Firstly, as judged by number of medications our patients had a lower disease severity than in other similar studies where patients were already on maximum tolerated topical therapy. Secondly, we specifically excluded eyes receiving pilocarpine thus ensuring its maximum therapeutic effect.
Patients already receiving regular pilocarpine may not benefit to the same extent from its use at the time of ALT. A study by Robin'5 supports this suggestion. In a group of patients receiving pilocarpine at the time of ALT, he recorded postoperative IOP rises in 57% of cases, higher than the 39% that we observed in our pilocarpine group. However, 54% of eyes in his pilocarpine group were already receiving the drug on a regular basis, whereas we excluded such patients from our study. Even if the prophylactic benefit ofpilocarpine is reduced by its regular use before ALT, it would seem appropriate to give an additional dose at the time of ALT to ensure that therapeutic levels are attained at the time when they are most beneficial.
The benefit of apraclonidine and pilocarpine in combination is apparent throughout the 3 hour study period. The fall in IOP which was observed in group C was significantly greater than in groups A and B at 1, 2, and 3 hours (Fig  1) . Figure 1 also shows the effect of administering apraclonidine and pilocarpine at different times. The maximum rate of fall in IOP in group A is in the first hour with a slight levelling off during the second and third hours. In group B there is no appreciable change in IOP during the first hour, but a rapid fall in IOP in the second and third hours. This suggests that the maximum effect ofapraclonidine occurs before that of pilocarpine. The combination of both drugs in group C results in a rapid fall in IOP that is maintained throughout the 3 hour measurement period. While this gives protection against IOP spikes for 3 hours or more after ALT, most spikes have been shown to occur within the first 2 hours. 16 Our results support these findings with 81% (17 eyes) of IOP spikes occurring in the first hour. Therefore it would seem appropriate to target maximum protection at the first 2 hours following ALT, and to this end perhaps we should have administered pilocarpine 1 hour preoperatively in the same way as apraclonidine.
The use of apraclonidine and pilocarpine in combination in our series of patients has been totally protective against clinically significant pressure spikes following ALT. Such protection will be of particular benefit (i) to eyes with severe optic disc cupping that are at risk ofvisual field and acuity loss, and (ii) to eyes in which 360 ratherthan 180 degrees ofALTare contemplated. However, if 360 degrees rather than 180 degrees ofALT are performed then pressure spikes could possibly be higher and even the combined use of apraclonidine and pilocarpine may be inadequate to prevent them completely.
We thank Alcon Laboratories, England for supporting this study. 
